OraPro-Flu - iosBio
Alternative Names: OraPro-Flu™- iosBioLatest Information Update: 28 Jul 2025
At a glance
- Originator iosBio
- Class Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in United Kingdom (PO, Capsule)
- 14 Jun 2021 iosBio plans a clinical trial for Influenza virus infections (Prevention) in 2021
- 18 Jan 2021 Early research in Influenza virus infections (Prevention) in United Kingdom (PO), prior to January 2021 (iosBio pipeline, January 2021)